Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships AstraZeneca (exclusive license, as amended December 16, 2025, to use Compugen's monospecific anti-TIGIT antibodies including COM902 for development of bi-specific and multi-specific antibody products; AstraZeneca developed rilvegostomig and is evaluating it)
Indications
Not disclosed(Phase 3)
Status note PD-1/TIGIT bi-specific antibody with a TIGIT component derived from COM902. Being evaluated by AstraZeneca in multiple Phase 3, Phase 2 and Phase 1 clinical trials. Filing notes recent failures in the TIGIT field (including discontinuation of the Phase 3 STAR-221 domvanalimab-based combination in upper GI cancers in December 2025 due to futility).
COM701
Phase 1 · ActiveModality: monoclonal antibody
Target PVRIG
Indications
Solid tumors(Phase 1)
Relapsed platinum-sensitive ovarian cancer (maintenance)(Stage not disclosed)
Status note Anti-PVRIG antibody. Phase 1 trials conducted as monotherapy, in combination with nivolumab, and in triplet combinations. Currently conducting the MAIA-ovarian platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum-sensitive ovarian cancer.
COM902
Phase 1 · ActiveModality: monoclonal antibody
Target TIGIT
Indications
Solid tumors(Phase 1)
Status note Therapeutic anti-TIGIT antibody evaluated in a Phase 1 dose escalation monotherapy trial. Based on negative data in the TIGIT field, the company currently believes COM902 has limited near-term value potential and does not plan to initiate new clinical trials with it; the decision may be revisited pending further TIGIT data from other companies.
GS-0321
Phase 1 · ActiveModality: monoclonal antibody
Aliases COM503
Target IL-18 binding protein (IL-18 pathway)
Partnerships Gilead (exclusive license to the preclinical anti-IL-18 binding protein antibody program, December 2023; Compugen is responsible for conducting a Phase 1 clinical trial of GS-0321 including regulatory matters)
Indications
Not disclosed(Phase 1)
Status note Antibody targeting the IL-18 pathway. Licensed to Gilead; currently being evaluated in a Phase 1 clinical trial that Compugen sponsors and conducts. Compugen is responsible only for Phase 1 clinical development.
Per-asset detail extracted from the 20-F filed 2026-03-02. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.